Pricing Trends and Overlapping Indications of Checkpoint Inhibitors for Cancer Treatment
Prices of checkpoint inhibitors have decreased only slightly since introduction. This may be partially explained by lack of overlapping indications, which hinders direct competition among within-class drugs. Expanding drug price negotiations or incentivizing comparative effectiveness research may help to promote competition and address high prices.
Authors
- Aaron Philip Mitchell (ORCID: https://orcid.org/0000-0003-3639-3515)
- Jeddeo M. Paul (ORCID: https://orcid.org/0000-0001-8525-1674)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Benjamin N. Rome (ORCID: https://orcid.org/0000-0001-5776-3293)
Institutions
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1200/op-25-00099
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00